• About Us
    • Our Company
    • Management & Board
  • Aceragen
  • Tilsotolimod
    • Toll-Like Receptor Activation
    • Publications & Presentations
  • Investor Relations
×

Interim Results From a Phase 1/2, Open-Label, Dose-Escalation Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom’s Macroglobulinemia

Interim Results From a Phase 1/2, Open-Label, Dose-Escalation Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

© 2022 Idera. All rights reserved.

  • Contact Us
  • Terms of Use
  • Privacy Policy